The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
Abstract
Introduction: Hyperthyroid Graves’ disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement; Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20+ depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P < 0.0001) and more significantly compared with IVGC (P < 0.05). Proptosis decreased significantly after RTX both in patients with active TAO (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < 0.003). The degree of inflammation (class 2) decreased significantly in response to RTX (ANOVA; P < 0.001). Relapse of active TAO was not observed in patients treated with RTX, but occurred in 10% of those treated with IVGC, who also experienced adverse effects more frequently (45 vs 33% of patients). Conclusions: RTX positively affects the clinical course of TAO, independently of either thyroid function or circulating antithyroid antibodies, including TRAb. If our findings are confirmed in large controlled studies, RTX may represent a useful therapeutic tool in patients with active TAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 962
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Autoantibodies to the Thyrotropin Receptor
SMITH, B. R., McLACHLAN, S. M., & FURMANIAK, J. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-106 · Cited by 575
Eckstein, A. K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., Heckmann, C., Esser, J., & Morgenthaler, N. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2813 · Cited by 477
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0148 · Cited by 423
Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens
Chiovato, L., Latrofa, F., Braverman, L. E., Pacini, F., Capezzone, M., Masserini, L., Grasso, L., & Pinchera, A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00010 · Cited by 364
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
Gerding, M. N., van der Meer, J. W. C., Broenink, M., Bakker, O., Wiersinga, W. M., & Prummel, M. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00959.x · Cited by 325
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Armengol, M. P., Juan, M., Lucas-Martín, A., Fernández-Figueras, M. T., Jaraquemada, D., Gallart, T., & Pujol-Borrell, R. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61762-2 · Cited by 306
B cells as antigen presenting cells
Rodríguez-Pinto, D. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2006.02.005 · Cited by 297
Balment, R. J., Lu, W., Weybourne, E., & Warne, J. M. (2006) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2005.12.022 · Cited by 257
Pathophysiology of Graves’ Ophthalmopathy: The Cycle of Disease
Bahn, R. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030010 · Cited by 229
Classification of the Eye Changes of Graves' Disease
WERNER, S. C. (1969) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-29-7-982 · Cited by 223
Cao, H. J., Wang, H.-S., Zhang, Y., Lin, H.-Y., Phipps, R. P., & Smith, T. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29615 · Cited by 195
Salvi, M., Vannucchi, G. M., Campi, I., Rossi, S., Bonara, P., Sbrozzi, F., Guastella, C., Avignone, S., Pirola, G., Ratiglia, R., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02119 · Cited by 145
Self-citationSalvi, M., Pedrazzoni, M., Girasole, G., Giuliani, N., Minelli, R., Wall, & Roti, E. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430197 · Cited by 143
Self-citationValyasevi, R. W., Harteneck, D. A., Dutton, C. M., & Bahn, R. S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8472 · Cited by 138
Fassi, D. E., Nielsen, C. H., Hasselbalch, H. C., & Hegedűs, L. D. (2006) · Thyroid · doi:10.1089/thy.2006.16.709 · Cited by 116
Han, R., & Smith, T. J. (2005) · Endocrinology · doi:10.1210/en.2005-1018 · Cited by 97
Sidner, R. A., Book, B. K., Agarwal, A., Bearden, C. M., Vieira, C. A., & Pescovitz, M. D. (2004) · Human Antibodies · doi:10.3233/hab-2004-13301 · Cited by 84
B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid Arthritis
Tsokos, G. C. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048114 · Cited by 79
Michelangeli, V. P., Poon, C., TAFT, J., Newnham, H. H., Topliss, D. J., & Colman, P. G. (1998) · Thyroid · doi:10.1089/thy.1998.8.119 · Cited by 78
The Spectrum and Significance of Autoantibodies Reacting with the Thyrotropin Receptor
Zakarija, M., & McKenzie, J. M. (1987) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30483-3 · Cited by 74
Fassi, D. E., Nielsen, C. H., Hasselbalch, H. C., & Hegedűs, L. D. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02140 · Cited by 70
Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon?
Mizokami, T., Salvi, M., & Wall, J. R. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345270 · Cited by 54
Self-citationValyasevi, R. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.5.2352 · Cited by 41
Segundo, C., Rodriguez, C. S., García-Poley, A., Aguilar‐Diosdado, M., Gavilán, I., Bellas, C., & Brieva, J. A. (2001) · Thyroid · doi:10.1089/105072501750302813 · Cited by 37
Kubota, S., Ohye, H., Nishihara, E., Kudo, T., Ito, M., Fukata, S., Amino, N., Kuma, K., & Miyauchi, A. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.735 · Cited by 31
Bellis, A. D., Bizzarro, A., Conte, M., Coronella, C., Solimeno, S., Perrino, S., Sansone, D., Guaglione, M., Wall, J. R., & Bellastella, A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01861.x · Cited by 30
Cited by
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationConsensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationSalvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3014 · Cited by 412
Self-citation
Metadata
- Authors
- Salvi, M., Vannucchi, G., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., Ratiglia, R., & Beck-Peccoz, P.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01
- Volume
- 156
- Issue
- 1
- Pages
- 33-40
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2110391738
- Cited by
- 264
- References
- 34
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.